Patents by Inventor Jochen Knolle

Jochen Knolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8501787
    Abstract: This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: August 6, 2013
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Grit Zahn, Roland Stragies, Frank Osterkamp, Gunther Zischinsky, Jochen Knolle, Gerd Hummel, Sascha Birkner, Ulrich Reineke
  • Publication number: 20110065760
    Abstract: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and S(O2)—NR14—, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y.
    Type: Application
    Filed: November 23, 2009
    Publication date: March 17, 2011
    Applicant: Jerini AG
    Inventors: Jochen KNOLLE, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Dirk Scharn, Roland Stragies, Christoph Gibson, Frank Osterkamp
  • Publication number: 20080221039
    Abstract: The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising B1 and B2 receptors.
    Type: Application
    Filed: July 4, 2006
    Publication date: September 11, 2008
    Inventors: Christoph Gibson, Gerd Hummel, Jochen Knolle, Ulrich Reineke, Thomas Tradler
  • Publication number: 20080194524
    Abstract: The present invention is related to compounds having formula (I) wherein the dashed line indicates a single or double bond or is absent and wherein A1-A9, Q, R1-R11, T, U, V, W1-W3, X1, X2, Y and Z are as defined in the claims and description, pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of a medicament for the treatment of diseases involving abnormal cell proliferation, undesired cell proliferation, abnormal mitosis and/or undesired mitosis.
    Type: Application
    Filed: December 18, 2004
    Publication date: August 14, 2008
    Applicant: JERINI AG
    Inventors: Jochen Knolle, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Christoph Gibson, Gunther Zischinsky
  • Patent number: 7348333
    Abstract: There are described cycloalkyl derivatives of the formula (I) R1—Y-A-B-D-E-F-G??(I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: March 25, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek, Robert McDowell, Robert Maurice Pitti, Sarah Catherine Bodary
  • Publication number: 20080021055
    Abstract: There are described cycloalkyl derivatives of the formula (I) R1—Y-A-B-D-E-F-G ??(I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Application
    Filed: August 21, 2007
    Publication date: January 24, 2008
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Stilz, Jean-Francois Gourvest, Denis Carniato, Thomas Gadek, Robert McDowell, Robert Pitti, Sarah Bodary
  • Patent number: 7259159
    Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: August 21, 2007
    Assignees: Sanofi-Aventis Deutschland GmbH, Genentech Inc.
    Inventors: Anuschirwan Peyman, David Will, Thomas R Gadek, Robert McDowell, Jean Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle
  • Publication number: 20070155712
    Abstract: This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.
    Type: Application
    Filed: March 24, 2005
    Publication date: July 5, 2007
    Applicant: Jerini AG
    Inventors: Grit Zahn, Roland Stragies, Frank Osterkamp, Gunther Zischinsky, Jochen Knolle, Gerd Hummel, Sascha Birkner, Ulrich Reineke
  • Publication number: 20070054904
    Abstract: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and —S(O2)—NR14—, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y.
    Type: Application
    Filed: September 18, 2003
    Publication date: March 8, 2007
    Applicant: Jerini AG
    Inventors: Jochen Knolle, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Dirk Scharn, Roland Stragies, Christoph Gibson, Frank Osterkamp
  • Publication number: 20060252813
    Abstract: The present invention is related to a compound of formula (I): A-B-E-D (I), wherein: A is selected from the group consisting Ra-L1-K-L2; and (II) B is either present or absent, but if B is present then B is (III), E is (IV), D is selected from the group comprising —(CR1Rm)rC(O)H, —(CR1Rm)rC—N, —CR1Rm)rNHNHC(O)NR5R6, —(CR1Rm)rC(O)(CRnRo)rc(O)OR7, —(CR1Rm)rC(O)(CrnRo)rC(O)NR8R9, —(CR1Rm)rCH(OH)(CrnRo)rC(O)U, —(CR1Rm)rC(O)W—(CR1Rm)rC(O)CH2W, —(CR1Rm)rC(O)haloalkyl, and —(CR1Rm)rC(O)(CRnRo)r—CHN2, and the use of said compounds as an inhibitor to rotamases.
    Type: Application
    Filed: December 23, 2003
    Publication date: November 9, 2006
    Inventors: Jochen Knolle, Mike Schumtkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Roland Stragies
  • Patent number: 6867208
    Abstract: The present invention relates to compounds of the formula I A—B—D—E—F—G??(I) in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: March 15, 2005
    Assignees: Hoechst Aktiengesellschaft, Genentech, Inc.
    Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
  • Publication number: 20040220148
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: October 24, 2003
    Publication date: November 4, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Hans Ulrich Stilz, Volkman Wehner, Jochen Knolle, Eckart Bartnik, Christoph Huels
  • Patent number: 6747016
    Abstract: The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonist and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or prolifertion of cells of the vascular smooth musculature.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: June 8, 2004
    Assignees: Aventis Pharma Deutschland GmbH, Genetech Inc.
    Inventors: Anuschirwan Peyman, Jochen Knolle, Thomas R Gadek, Jean-Francois Gourvest, Jean-Marie Ruxer
  • Patent number: 6747148
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 8, 2004
    Assignees: Hoechst Marion Roussel Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6723727
    Abstract: The present invention relates to compounds of the formulae I and Ia in which X, Y, W, Wa, G and Ga have the meanings given in the patent claims, and their physiologically tolerable salts and their prodrugs, their preparation, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations comprising them. The compounds of the formula I are vitronectin receptor antagonists and can be employed, for example, as inhibitors of bone resorption and for the treatment of osteoporosis.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: April 20, 2004
    Assignees: Hoechst Aktiengesellschaft, Genentech
    Inventors: Anuschirwan Peyman, Jochen Knolle, Volkmar Wehner, Gerhard Breipohl, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek
  • Patent number: 6660728
    Abstract: The present invention relates to thienyl substituted acylguanidine derivatives, such as compounds of formula (I) in which R1, R2, R4, R6, A, B and D have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the present invention are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of thienyl substituted acylguanidines, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: December 9, 2003
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Publication number: 20030203896
    Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.
    Type: Application
    Filed: January 27, 2003
    Publication date: October 30, 2003
    Inventors: Anurschirwan Peyman, David Will, Thomas R Gadek, Jochen Knolle, Robert McDowell, Jean-Francois Gourvest, Jean-Marie Ruxer
  • Patent number: 6620820
    Abstract: The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments. The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: September 16, 2003
    Assignees: Hoechst Aktiengesellschaft, Genentech, Inc.
    Inventors: Volkmar Wehner, Jochen Knolle, Hans Ulrich Stilz, Denis Carniato, Jean-Francois Gourvest, Tom Gadek, Robert McDowell
  • Publication number: 20030153557
    Abstract: The present invention relates to thienyl substituted acylguanidine derivatives, such as compounds of formula (I) in which R1, R2, R4, R6, A, B and D have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the present invention are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of thienyl substituted acylguanidines, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 14, 2003
    Applicant: Aventis Pharma Deutschland GmbH and Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6602878
    Abstract: Acylquanidines of the formula wherein the substituents are defined as in the specification which are antagonists of the vitronectin receptor and inhibitors of cell adhesion and bone resorption mediated by the osteoclasts.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: August 5, 2003
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Jean-Marie Ruxer, Sarah C. Bodary